1spatial Share Discussion Threads

[geoffmanana] 11/4/2007 14:39

Good posts.

Any idea what level 2 is looking like?......thanks.

[scrutable] 11/4/2007 14:25

It is beginning to look as though AtuRNAi compounds are being used to lay the foundation stones of a major new class of therapies as significant in medecine as the discovery of antibiotics. Why else would Pfizer agree to lay out up to $95m without acquiring control?

Not only do SPA ( or rather the acquired Atugen, in Berlin) have the potential to treat cancer, but also inherited and infectious diseases for many of which there is currently no hope of a cure.

SPA is (again through Atugen)a global leader, and now, with its core patent covering 38 claims, it is well protected and free to plunge into the market undeterred by fears of IP theft.

Some acquisition that - Atugen - for only £6.2m two years ago, ......and after venture funds had invested £37m in the target. Read more on 'you know where'

[scrutable] 11/4/2007 14:01

Apart from the obvious bull points picked out by IC and others did you notice

"SPA is also in touch with others having capabilities and complementary technologies, which can add value to SPA's core RNAi expertise. Announcements of significant collaborations are expected in '07...."

"SPA expects to enhance shareholder value over the coming year, despite a
significant increase in R&D and infrastructure costs, as the lead siRNA
molecules move into the clinic later in the year and the Group establishes
operations in the US.....".

"The increase in revenue was swallowed up by an equivalent increase in R&D,
But on a like for like basis (comparing a full year in '05 with a full year in '06) the increase was only 13%. Similarly the 9% increase in admin for the period masked an actual 10% fall in the monthly rate...."

The above points are made with many others in 6pp of update, analysis and comment on 'you know where'

[licom] 11/4/2007 12:01

UPDATE - SR Pharma, The Share price has been well contained within an upward trend
channel recovering rapidly at 177%/pa, to regain, over the last five months, all the ground lost during a six year decline.

[aglenn] 11/4/2007 09:56

No...out and about at moment.

[alwaysbanking] 11/4/2007 09:51

Aglenn was that your add that caused the bounce.

[aglenn] 11/4/2007 09:18

Thanks AB...seems to be holding at the resistance you mentioned...I may even add today.

[alwaysbanking] 10/4/2007 23:29

Aglenn, sorry missed your post been in Manchester all day queuing for a Chinese Visa - Off there on the 30th inst. Disappointed with the share price today but he mms will steadily walk it down ahead of the EGM to pick up the weak holders. Seller around providing the buys until he/she clears very much weak. Plenty of resistence around the 73p so would expect the 74 - 76 range to be toyed with. Once the EGM has taken place then get ready for acclerated news. Pfizer resukts were phenominal from memory it was 1.6 billion dollar profit (I think in the US thats 1million million dollars) - New Financial Year for them means New money and SRPharma are right up their street. Pfizer will buy them out of their loose change and at a PREMIUM - I'd rather be in than out. The 1.50 broker guidancw may be History in two to three weeks. I will echo that directors buys are significant indicators and 75.75p shows that there is expected upside in the not too distant future.
My personal interpretation of my personal chart understanding is showing an imminent rise to the 77 -78p range. The 20day ma base is rising sharper than the previous days and a bounce off that could occur by Thursday.

[aglenn] 10/4/2007 10:32

Morning gents.....another slow and slightly downbeat start to the week....are we expecting a push down before a rise.? AlwaysBanking...whats your chart saying.?

[mike111d] 09/4/2007 18:01

Just as long as you don't go hopping from one pad to another, as I am hoping that hanging around here is going to be "rivet"ing in the coming weeks.

[3frog] 09/4/2007 17:54

Fancy a cheaper pond so I can dip in more of my toes in here.

[geoffmanana] 09/4/2007 17:16

You've sold your "pad" then 3frog........sorry.

[3frog] 09/4/2007 11:52

I'll be buying more too sooner rather than later when my house sale has completed. Hopefully next week.

[buzzzzzzzz] 07/4/2007 15:53

Lets not forget that the company is currently talking to several companies who want to take an equity stake in SPA.

Ian Ross bought 100k at 75.5p I think that tells us all we need to know.

I expect this to happen sooner rather than later!

[alwaysbanking] 05/4/2007 23:24

SR Pharma is a leader in RNAi therapeutics, which is a Nobel Prize winning
technology that "silences" genes linked to the onset of disease. The Company
has developed novel, chemically modified proprietary siRNA molecules
("AtuRNAi"), which have a number of advantages over conventional siRNA
molecules including enhanced stability against nuclease degradation. In
addition, the Company has developed a proprietary delivery system ("AtuPLEX"),
which increases bioavailability, circulation times and functional intracellular
uptake of siRNA molecules.
SR Pharma expects to begin the clinical development of its proprietary AtuRNAi
therapeutic molecules for systemic cancer indications in 2007. SR Pharma has
sublicensed the AtuRNAi compound RTP-801i to Pfizer through its collaboration
partner Quark Biotech Inc. for the treatment of Age-related Macular
Degeneration (AMD) and a number of other indications. This compound entered the
clinic in early 2007. In addition SR Pharma has licensed a further AtuRNAi
compound, AKIi-5, to Quark Biotech Inc. This compound has been granted an IND
for acute kidney injury and is expected to enter the clinic in 2007.
SR Pharma also owns a proprietary Mycobacterium vaccae-based technology and
related products. Currently the Company is in discussions with third parties
regarding the co-development and out-licensing of these products.

[mike111d] 05/4/2007 22:40

Here is what IC had to say:

SR PHARMA (SPA)

SR Pharma - which is changing its name to Silence Therapeutics - might look like just another risky biotech, but it has interesting irons in the fire. First, its RNAi technology, which 'silences' disease-causing genes, is very hot right now after a group of scientists working on RNAi last year won the Nobel Prize. Second, on the strength of this technology, the company recently signed a deal with Pfizer worth up to $95m plus royalties. The deal was particularly significant considering that SR's products were not yet in Phase I trials.

And third, SR Pharma's partner, Quark Biotech, has taken the company's product for age-related macular (eye) degeneration into Phase I trials, and is now hoping to begin Phase I studies of its kidney injury product. Chief executive Iain Ross says SR's own cancer drug should enter studies this year, too.
The company's intellectual property situation has also improved, with a European patent secured in January, and it is in discussions to sign further licensing deals.


________________________________________
Ord price: 75p Market value: £85m
Touch: 75-76p 12-month High: 84.25p Low: 11.25p
Dividend yield: nil PE ratio: na
Net asset value: 14p* Net cash: £8.8m
*Includes intangible assets of £6.2m, or 6p a share

________________________________________
Year to Turnover Pre-tax Earnings Dividend
31 Dec (£m) profit (£m) per share (p) per share (p)
________________________________________
2004 0.15 -3.31 -9.71 nil
2005 0.51 -3.63 -5.89 nil
2006 1.95 -3.94 -4.02 nil
% change +283 - - -
________________________________________
Last IC view: Buy, 73p, 23 Mar 2007


IC View - The shares have risen sevenfold since last August, so it might be tempting to pocket some profits. But, following the $1.1bn acquisition of rival US company Sirna Therapeutics by Merck late last year, SR Pharma could itself become a bid target. A speculative buy.

[aglenn] 05/4/2007 18:26

AB,you seem to get most of your calls right....whats your secret.? Can we bottle and sell it.?

Happy easter all and may the share price steadily rise for a good summer

[geoffmanana] 05/4/2007 17:29

Tuesday (new tax year) may be better.....lets hope so.
Happy Easter one and all.

[chicken charlie] 05/4/2007 12:29

Investors Chronicle rates it as a BUY in its company results.

[alwaysbanking] 04/4/2007 20:22

Tomorrow will see a rise back toward the 76p area

[alwaysbanking] 04/4/2007 20:21

Added 25k at 73.5p. Although I think that it will be steadily walked down without news up until the EGM, id rather be in than out especially reading on Bloomberg that Merck may not get an American rubberstamp for one of its leading medicines so perhaps they may go for SPA as a little compensation.

[geoffmanana] 04/4/2007 17:05

So close to adding at 73.5p...probably could have got 73p.

[3frog] 04/4/2007 16:51

anyone here added today on the dip.

[texicon] 04/4/2007 14:52

Maybe better value tomorrow.